UNICHEMLABPharmaceuticals
Unichem Laboratories Ltd — Cash Flow Statement
₹293.45
-4.90%
Unichem Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -144.38 Cr | -8.55 Cr | -129.41 Cr | -386.61 Cr | — |
| Repayment Of Debt | -25.66 Cr | -25.66 Cr | -25.66 Cr | -9.52 Cr | — |
| Issuance Of Debt | 50.39 Cr | 0.00 | 0.00 | 124.19 Cr | — |
| Capital Expenditure | -137.36 Cr | -22.55 Cr | -44.32 Cr | -127.00 Cr | — |
| End Cash Position | 89.58 Cr | 154.75 Cr | 183.75 Cr | 109.20 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -0.68 Cr | 12.91 Cr | 38.13 Cr | -2.28 Cr | — |
| Beginning Cash Position | 154.75 Cr | 183.75 Cr | 109.20 Cr | 77.46 Cr | — |
| Changes In Cash | -64.49 Cr | -41.91 Cr | 36.42 Cr | 34.01 Cr | — |
| Financing Cash Flow | 183.76 Cr | -106.31 Cr | -81.30 Cr | 191.23 Cr | — |
| Interest Paid Cff | -19.57 Cr | -22.23 Cr | -16.29 Cr | -5.08 Cr | — |
| Cash Dividends Paid | -0.34 Cr | -0.21 Cr | -28.25 Cr | -28.36 Cr | — |
| Net Issuance Payments Of Debt | 209.57 Cr | -78.48 Cr | -33.36 Cr | 229.52 Cr | — |
| Net Short Term Debt Issuance | 184.84 Cr | -52.82 Cr | -7.69 Cr | 114.85 Cr | — |
| Net Long Term Debt Issuance | 24.73 Cr | -25.66 Cr | -25.66 Cr | 114.67 Cr | — |
| Long Term Debt Payments | -25.66 Cr | -25.66 Cr | -25.66 Cr | -9.52 Cr | — |
| Long Term Debt Issuance | 50.39 Cr | 0.00 | 0.00 | 124.19 Cr | — |
| Investing Cash Flow | -241.23 Cr | 50.40 Cr | 202.81 Cr | 102.40 Cr | — |
| Net Other Investing Changes | -24.64 Cr | -1.80 Cr | 3.30 Cr | 0.39 Cr | — |
| Interest Received Cfi | 1.69 Cr | 0.57 Cr | 0.94 Cr | 14.74 Cr | — |
| Dividends Received Cfi | 0.00 | 0.00 | 59000.00 | 10.01 Cr | — |
| Net Investment Purchase And Sale | 1.36 Cr | 65.23 Cr | 236.51 Cr | 204.09 Cr | — |
| Sale Of Investment | 1.36 Cr | 65.23 Cr | 236.51 Cr | 204.09 Cr | — |
| Net Business Purchase And Sale | -84.45 Cr | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Business | -84.45 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | -135.19 Cr | -13.60 Cr | -37.94 Cr | -126.84 Cr | — |
| Sale Of PPE | 2.17 Cr | 8.95 Cr | 6.37 Cr | 0.16 Cr | — |
| Purchase Of PPE | -137.36 Cr | -22.55 Cr | -44.32 Cr | -127.00 Cr | — |
| Operating Cash Flow | -7.02 Cr | 14.00 Cr | -85.09 Cr | -259.61 Cr | — |
| Taxes Refund Paid | -16.42 Cr | -6.37 Cr | -12.21 Cr | -7.62 Cr | — |
| Change In Working Capital | -293.89 Cr | -91.99 Cr | -29.36 Cr | -354.43 Cr | — |
| Change In Payable | -2.37 Cr | -7.15 Cr | 119.26 Cr | -15.45 Cr | — |
| Change In Inventory | -252.48 Cr | -79.45 Cr | -25.01 Cr | -61.88 Cr | — |
| Change In Receivables | -39.04 Cr | -5.39 Cr | -123.61 Cr | -277.10 Cr | — |
| Other Non Cash Items | 18.18 Cr | 21.99 Cr | 16.70 Cr | -0.68 Cr | — |
| Stock Based Compensation | 2.12 Cr | 3.08 Cr | 1.05 Cr | 2.85 Cr | — |
| Provisionand Write Offof Assets | 1.41 Cr | 126.26 Cr | 0.89 Cr | -0.22 Cr | — |
| Depreciation And Amortization | 124.56 Cr | 123.16 Cr | 113.44 Cr | 91.23 Cr | — |
| Amortization Cash Flow | 11.23 Cr | 0.00 | — | — | — |
| Depreciation | 113.33 Cr | 123.16 Cr | 113.44 Cr | 91.23 Cr | — |
| Gain Loss On Investment Securities | 0.66 Cr | -71.22 Cr | -4.03 Cr | -13.14 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 4.01 Cr | -1.00 Cr | 2.66 Cr | -7.22 Cr | — |
| Gain Loss On Sale Of PPE | -0.95 Cr | -4.86 Cr | -1.28 Cr | 0.23 Cr | — |
| Net Income From Continuing Operations | 154.59 Cr | -84.96 Cr | -176.36 Cr | 21.97 Cr | — |
| Sale Of Business | — | — | 0.00 | 0.00 | — |
| Issuance Of Capital Stock | — | — | — | — | 0.00 |
| Common Stock Dividend Paid | — | — | — | — | -28.66 Cr |
| Net Common Stock Issuance | — | — | — | — | 0.00 |
| Common Stock Issuance | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Unichem Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.